Sichuan Baili Pharmaceutical Co., Ltd.

Overview

Sichuan Baili Pharmaceutical Co., Ltd. is a modern biopharmaceutical enterprise integrating drug research and development, production, and marketing, specializing in chemical drug preparations, Chinese patent medicines, and innovative biological drugs. The company has a comprehensive drug R&D and production capability, including small molecule chemical drugs, large molecule biological drugs, and antibody-drug conjugates (ADC drugs).

Therapeutic areas

API / Drug Master Files

Sichuan Baili Pharmaceutical Co., Ltd. holds 58 active (83 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• LEMBOREXANTActive2026-03-30
• ICOSAPENT ETHYLActive2026-03-24
• ABEMACICLIBActive2026-03-18
• NUSINERSEN SODIUMActive2025-12-26
• DAROLUTAMIDEActive2025-12-15
• INDIGOTINDISULFONATE SODIUMActive2025-11-27
• SODIUM ZIRCONIUM CYCLOSILICATEActive2025-09-23
• LANREOTIDE ACETATEActive2025-08-09
• SUCROFERRIC OXYHYDROXIDEActive2025-07-30
• CYTISINEActive2025-07-30
• NALOXONEActive2025-07-11
• OMEGA-3-ACID ETHYL ESTERS 90Active2025-05-29
• IRON SUCROSEActive2025-05-15
• LENVATINIB MESYLATEActive2025-03-24
• URSODIOLActive2025-03-20

Showing 15 of 83 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Sichuan Baili Pharmaceutical Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.